39 results on '"Eric Descombes"'
Search Results
2. Acute Renal Failure in a Patient with Rivaroxaban-Induced Hypersensitivity Syndrome: A Case Report with a Review of the Literature and of Pharmacovigilance Registries
- Author
-
Gisela Marcelino, Ould Maouloud Hemett, and Eric Descombes
- Subjects
Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Direct oral anticoagulants (DOACs) are among the most commonly prescribed medications, and DOAC-associated kidney dysfunction may be a problem that is underrecognized by clinicians. We report on the case of an 82-year-old patient who, two weeks after the prescription of rivaroxaban for atrial fibrillation, was hospitalized for a drug-induced hypersensitivity syndrome whose main clinical manifestations were low-grade fever with a petechial rash in the legs and acute renal failure (ARF). Within one week after rivaroxaban withdrawal, the patient’s clinical condition improved and the renal function normalized. In a review of the literature, we only found five case reports of rivaroxaban-related ARF: two patients had tubulo-interstitial nephritis (TIN), two had anticoagulant-related nephropathy (ARN), and the last one had IgA nephropathy. As some recent publications suggest that kidney injury due to anticoagulation drugs may be largely underdiagnosed, we also analyzed the data from the VigiAccess database, the World Health Organization pharmacovigilance program that collects drug-related adverse events from 134 national registries worldwide. Among all the rivaroxaban-associated adverse events reported in VigiAccess since 2006, 4,323 (3.5%) were renal side effects, of which 2,351 (54.3%) were due to unspecified ARF, 363 (8.4%) were due to renal hemorrhage (characteristically associated with ARN), and 24 (0.6%) were due to TIN. We also compared these results with those reported in VigiAccess for other DOACs and vitamin K antagonists. This analysis suggests that the frequency of renal adverse events associated with rivaroxaban and other DOACs may be appreciably higher than what one might currently consider based only on the small number of fully published cases.
- Published
- 2020
- Full Text
- View/download PDF
3. Bilateral Ureteral Stenosis with Hydronephrosis as First Manifestation of Granulomatosis with Polyangiitis (Wegener’s Granulomatosis): A Case Report and Review of the Literature
- Author
-
Joelle Suillot, Jürg Bollmann, Samuel Rotman, and Eric Descombes
- Subjects
Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Ureteral stenosis is a rare manifestation of granulomatosis with polyangiitis (formerly known as Wegener’s granulomatosis). We report the case of a 76-year-old woman with progressive renal failure in which bilateral hydronephrosis due to ureteral stenosis was the first manifestation of the disease. Our patient also had renal involvement with pauci-immune crescentic glomerulonephritis associated with high titers of anti-proteinase 3 c-ANCAs, but no involvement of the upper or lower respiratory tract. The hydronephrosis and renal function rapidly improved under immunosuppressive therapy with high-dose corticosteroids and intravenous pulse cyclophosphamide. We reviewed the literature and found only ten other reported cases of granulomatosis with polyangiitis/Wegener’s granulomatosis and intrinsic ureteral stenosis: in two cases, the presenting clinical manifestation was unilateral hydronephrosis and in only two others was the hydronephrosis bilateral, but this complication developed during a relapse of the disease. This case emphasizes the importance of including ANCA-related vasculitis in the differential diagnosis of unusual cases of unilateral or bilateral ureteral stenosis.
- Published
- 2020
- Full Text
- View/download PDF
4. Oral Postdialysis Cholecalciferol Supplementation in Patients on Maintenance Hemodialysis: A Dose-Response Approach
- Author
-
Eric Descombes, Benoit Fellay, Ould Maouloud Hemett, Jean-Luc Magnin, and Gilbert Fellay
- Subjects
Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
The aim of the present study was to evaluate the dose of postdialysis cholecalciferol needed to maintain the 25-hydroxyvitamin D [25(OH)D] levels in the optimal range of 75–150 nmol/L. Twenty-six patients who had low baseline 25(OH)D levels (mean 27.5±14.9 nmol/L) were studied. The 25(OH)D levels were measured every 2 months for one year. During the first two months, all the patients received 2000 IU of cholecalciferol after each hemodialysis (=6000 IU/wk). Thereafter, the dose was individualized and adapted every 2 months by administering 1 to 6 cholecalciferol tablets (2000 IU each) per week (total weekly dose = 2000–12000 IU/wk). During cholecalciferol supplementation, the 25(OH)D concentrations rapidly increased from baseline to 140.1±28.3 nmol/L at month 6 and 95.6±20.9 nmol/L at month 12. At month twelve, 86% of the patients had 25(OH)D levels within the target range with a mean dose of 5917±4106 IU/wk of cholecalciferol; however, the amount needed to maintain these levels varied widely from 0 (n=2) to 12000 IU/wk (n=5). In conclusion, postdialysis cholecalciferol prescription is quite effective in correcting vitamin D deficiency/insufficiency, but the amount of cholecalciferol needed to maintain the 25(OH)D levels within the optimal range over the long-term varies widely among patients and must be individualized.
- Published
- 2014
- Full Text
- View/download PDF
5. Urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) and contrast-induced acute kidney injury after coronary angiogram
- Author
-
Tilman Perrin, Eric Descombes, Jean-Luc Magnin, Magali Gachet, Ould Maouloud Hemett, Daniel Hayoz, Valérie Stolt, Gérard Baeriswyl, Jean-Christophe Stauffer, Jean-Jacques Goy, Mario Togni, and Stephane Cook
- Subjects
acute kidney injury ,Contrast medium volume ,Contrast-induced acute kidney injury ,Percutaneous coronary procedure ,Urinary neutrophil gelatinase-associated lipocalin ,Medicine - Abstract
QUESTIONS UNDER STUDY: Diagnosis of acute kidney injury (AKI) relies on measurement of serum creatinine (SCr). SCr is a late marker of impaired renal function. Urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) has given encouraging results for an early and sensitive detection of AKI. This cohort study was conducted (1) to assess the value of uNGAL as early marker of contrast-induced AKI (CI-AKI) in unselected patients undergoing percutaneous coronary procedure (PCP) and (2) to investigate whether uNGAL levels correlate with the volume of contrast medium (CM) used during the procedure. METHODS: We enrolled 244 consecutive adult patients undergoing PCP done with the low-osmolar CM Iomeprolum (median volume of CM 122 [88–168] ml per procedure). uNGAL was measured at its peak with a standardised clinical laboratory platform (ARCHITECT uNGAL assay, Abbott). RESULTS: Overall, the post-PCP uNGAL levels were extremely low in our cohort with a median value of 7.7 [4.0–14.5] ng/ml (N ≤132 ng/ml). Twenty-five (10%) patients developed CI-AKI according to the classical diagnostic criteria (≥25% or ≥44.2 µmol/l increase in SCr) and 8 (3.3%) patients according to the AKIN criteria. Regardless of the definition considered, uNGAL levels did not significantly differ in patients with or without CI-AKI. Similarly, we found no significant correlation between the volume of CM used and the post-PCP uNGAL levels (r = –0.11). CONCLUSIONS: In a large cohort of unselected adult patients, uNGAL measured four to six hours after PCP was ineffective to predict the risk of CI-AKI and did not correlate with the volume of CM used during the procedure.
- Published
- 2013
- Full Text
- View/download PDF
6. Contrast-induced nephropathy in invasive cardiology
- Author
-
Tilman N.U. Perrin, Eric Descombes, and Stephane Cook
- Subjects
biomarkers ,contrast-induced nephropathy (CIN) ,percutaneous coronary interventions (PCI) ,Review ,Medicine - Abstract
Contrast-induced nephropathy (CIN) is an acute renal injury due to the renal toxicity of iodinated contrast media. It is classically defined as a relative (≥25%) or absolute (≥0.5 mg/dl; 44 μmol/l) increase in serum creatinine from baseline value. CIN accounts for 10 to 15% of hospital-acquired acute renal failure and may rarely lead to irreversible renal function loss. Following percutaneous coronary intervention, reported incidence of CIN varies between 0 to more than 20%, depending on the prevalence of risk factors and used definition. Nowadays, the diagnosis of CIN relays on serum creatinine monitoring, although it is a late marker of acute kidney injury. Given the expanding number of percutaneous coronary interventions made in outpatient settings and the morbidity and mortality associated with CIN, early detection of CIN is of utmost clinical relevance. Several plasmatic and urinary biomarkers have been studied in that view, with plasmatic cystatine-C and urinary NGAL being the most promising. As no treatment specifically targets CIN once it develops, the main goal for clinicians remains prevention, with hydration status optimisation being the only proven strategy to date. Here, we will review the recent evidence concerning CIN, its incidence, proposed early diagnostic biomarkers, as well as its treatment and prognostic implication.
- Published
- 2012
- Full Text
- View/download PDF
7. Acute Renal Failure in a Patient with Rivaroxaban-Induced Hypersensitivity Syndrome: A Case Report with a Review of the Literature and of Pharmacovigilance Registries
- Author
-
Ould Maouloud Hemett, Gisela Marcelino, and Eric Descombes
- Subjects
medicine.medical_specialty ,Rivaroxaban ,business.industry ,Renal Hemorrhage ,Renal function ,Case Report ,Atrial fibrillation ,Petechial rash ,medicine.disease ,Diseases of the genitourinary system. Urology ,Nephropathy ,Nephrology ,Internal medicine ,Pharmacovigilance ,medicine ,RC870-923 ,business ,Adverse effect ,medicine.drug - Abstract
Direct oral anticoagulants (DOACs) are among the most commonly prescribed medications, and DOAC-associated kidney dysfunction may be a problem that is underrecognized by clinicians. We report on the case of an 82-year-old patient who, two weeks after the prescription of rivaroxaban for atrial fibrillation, was hospitalized for a drug-induced hypersensitivity syndrome whose main clinical manifestations were low-grade fever with a petechial rash in the legs and acute renal failure (ARF). Within one week after rivaroxaban withdrawal, the patient’s clinical condition improved and the renal function normalized. In a review of the literature, we only found five case reports of rivaroxaban-related ARF: two patients had tubulo-interstitial nephritis (TIN), two had anticoagulant-related nephropathy (ARN), and the last one had IgA nephropathy. As some recent publications suggest that kidney injury due to anticoagulation drugs may be largely underdiagnosed, we also analyzed the data from the VigiAccess database, the World Health Organization pharmacovigilance program that collects drug-related adverse events from 134 national registries worldwide. Among all the rivaroxaban-associated adverse events reported in VigiAccess since 2006, 4,323 (3.5%) were renal side effects, of which 2,351 (54.3%) were due to unspecified ARF, 363 (8.4%) were due to renal hemorrhage (characteristically associated with ARN), and 24 (0.6%) were due to TIN. We also compared these results with those reported in VigiAccess for other DOACs and vitamin K antagonists. This analysis suggests that the frequency of renal adverse events associated with rivaroxaban and other DOACs may be appreciably higher than what one might currently consider based only on the small number of fully published cases.
- Published
- 2020
8. Monthly measurement of high-sensitivity cardiac troponins T and creatine kinase in asymptomatic chronic hemodialysis patients: A one-year prospective study
- Author
-
Stéphane Gremaud, Benoît Fellay, Ould Maouloud Hemett, Jean‐Luc Magnin, and Eric Descombes
- Subjects
Aged, 80 and over ,Troponin T ,Nephrology ,Renal Dialysis ,Humans ,Hematology ,Prospective Studies ,Middle Aged ,Creatine Kinase ,Biomarkers ,Aged - Abstract
Cardiology guidelines recommend measuring high-sensitivity cardiac troponin (hs-cTn) for the diagnostic work-up of acute coronary syndromes (ACS). Many hospitals measure hs-cTnT, but preliminary data have shown that hs-cTnT is higher than normal in many hemodialysis patients without evidence of ACS. The purpose of this study was therefore to determine the hs-cTnT levels every month for 1 year in asymptomatic hemodialysis patients, in order to assess their changes over time relative to creatine kinase.Fourty-four hemodialysis patients (mean age 67 ± 14 years) were included. The predialysis levels of fifth-generation hs-cTnT, CK, and CK-MB were measured every month for 1 year using a Cobas® 6000 analyzer (Roche Diagnostics, Switzerland).Almost 100% of hs-cTnT measurements were higher than normal (N 14 ng/L); the mean ± SD annual level was 84 ± 59 ng/L, ranging from a minimum of 24 ± 2 to 241 ± 28 ng/L in individual patients. The mean levels of CK and CK-MB were normal. Thirteen myocardial infarctions were analyzed, which were all associated with an initial elevation in hs-cTnT45% from the individual baseline value. By comparison, CK and CK-MB only increased in 38% and 31% of these myocardial infarctions, respectively.hs-cTnT is persistently higher than normal in chronic hemodialysis patients. Standard algorithms for diagnosing ACS can obviously not be used and alternative diagnostic strategies need to be developed. According to our data, and given the huge variation in baseline hs-cTnT levels among patients, the use of higher cut-offs as proposed in the literature cannot be recommended. Instead, we consider that hs-cTnT should be checked at regular intervals (e.g., every 3-6 months) in order to establish individual baseline levels for hs-cTnT. This approach, in most instances, not only makes it possible to more rapidly rule-in but also to rapidly rule-out, cases of ACS in hemodialysis patients who develop cardiac symptoms.
- Published
- 2021
9. Comment on: 'Post-Dialysis Parenteral Antimicrobial Therapy in Patients Receiving Intermittent High-Flux Haemodialysis'
- Author
-
Ould Maouloud Hemett, Eric Descombes, Christian Chuard, and Veronique Erard
- Subjects
medicine.medical_specialty ,business.industry ,Pharmacology toxicology ,MEDLINE ,Review Article ,Antimicrobial ,Anti-Bacterial Agents ,High flux ,Pharmacotherapy ,Anti-Infective Agents ,Renal Dialysis ,Post dialysis ,medicine ,Humans ,Kidney Failure, Chronic ,Pharmacology (medical) ,In patient ,cardiovascular diseases ,Intensive care medicine ,business - Abstract
Patients with end-stage renal disease (ESRD) requiring intermittent hemodialysis (IHD) are at increased risk of infection, which represents a leading cause of mortality in this population. The use of additional vascular access devices such as peripherally inserted central catheters to treat such infections should be minimized in patients with ESRD requiring IHD in order to mitigate complications such as infection and thrombosis and to maintain venous patency for hemodialysis access. Intravenous antimicrobial dosing following IHD has the advantages of avoiding additional access devices and providing convenience for patients and providers. Vancomycin, cefazolin, and aminoglycosides have historically been regarded as the primary intravenous antimicrobials administered with IHD given their relatively low cost, convenient dosing, and longevity of clinical use. Despite this, a growing body of literature is evaluating the use of an expanded list of antimicrobials that may be employed using post-dialysis dosing for patients requiring IHD; however, the available data are largely limited to pharmacokinetic studies and small cohorts of infected patients or uninfected subjects. Post-dialytic dosing of intravenous antimicrobials may be considered on a patient-by-patient basis after careful consideration of clinical, microbiological, and logistical factors that may influence the probability of treatment success. This document reviews and evaluates currently available information on the post-dialytic administration of an expanded list of intravenous antimicrobials in the setting of thrice-weekly, high-flux IHD.
- Published
- 2021
10. Bilateral Ureteral Stenosis with Hydronephrosis as First Manifestation of Granulomatosis with Polyangiitis (Wegener’s Granulomatosis): A Case Report and Review of the Literature
- Author
-
Eric Descombes, Joelle Suillot, Samuel Rotman, and Jurg Bollmann
- Subjects
030203 arthritis & rheumatology ,Wegener s ,medicine.medical_specialty ,business.industry ,030232 urology & nephrology ,Ureteral stenosis ,Renal function ,Case Report ,medicine.disease ,urologic and male genital diseases ,Diseases of the genitourinary system. Urology ,03 medical and health sciences ,0302 clinical medicine ,Nephrology ,medicine ,Radiology ,RC870-923 ,Differential diagnosis ,Complication ,business ,Granulomatosis with polyangiitis ,Vasculitis ,Hydronephrosis - Abstract
Ureteral stenosis is a rare manifestation of granulomatosis with polyangiitis (formerly known as Wegener’s granulomatosis). We report the case of a 76-year-old woman with progressive renal failure in which bilateral hydronephrosis due to ureteral stenosis was the first manifestation of the disease. Our patient also had renal involvement with pauci-immune crescentic glomerulonephritis associated with high titers of anti-proteinase 3 c-ANCAs, but no involvement of the upper or lower respiratory tract. The hydronephrosis and renal function rapidly improved under immunosuppressive therapy with high-dose corticosteroids and intravenous pulse cyclophosphamide. We reviewed the literature and found only ten other reported cases of granulomatosis with polyangiitis/Wegener’s granulomatosis and intrinsic ureteral stenosis: in two cases, the presenting clinical manifestation was unilateral hydronephrosis and in only two others was the hydronephrosis bilateral, but this complication developed during a relapse of the disease. This case emphasizes the importance of including ANCA-related vasculitis in the differential diagnosis of unusual cases of unilateral or bilateral ureteral stenosis.
- Published
- 2020
11. Three-times-weekly, post-dialysis cefepime therapy in patients on maintenance hemodialysis: a retrospective study
- Author
-
Veronique Erard, Christian Chuard, Ould Maouloud Hemett, Filipe Martins, and Eric Descombes
- Subjects
Male ,0301 basic medicine ,medicine.medical_treatment ,030232 urology & nephrology ,Gastroenterology ,Cohort Studies ,0302 clinical medicine ,Outpatient clinic ,Pharmacology (medical) ,Cefepime ,Infusions, Intravenous ,Middle Aged ,Staphylococcal Infections ,Anti-Bacterial Agents ,Beta-lactam antibiotics ,Hemodialysis ,Anesthesia ,Female ,Drug Monitoring ,medicine.symptom ,Research Article ,medicine.drug ,Staphylococcus aureus ,medicine.medical_specialty ,Outpatient Clinics, Hospital ,030106 microbiology ,Renal function ,Microbial Sensitivity Tests ,Anuria ,Drug Administration Schedule ,03 medical and health sciences ,Pharmacokinetics ,Renal Dialysis ,Internal medicine ,Gram-Negative Bacteria ,medicine ,Humans ,Renal Insufficiency, Chronic ,Dialysis ,Aged ,Retrospective Studies ,Pharmacology ,business.industry ,Retrospective cohort study ,Cephalosporins ,Renal Elimination ,Gram-Negative Bacterial Infections ,business - Abstract
Background In hemodialysis patients, post-dialysis treatment with intravenous antibiotics permits even severe infections to be managed on an outpatient basis. Cefepime is a fourth-generation cephalosporin with a broad spectrum of action in monotherapy. We report on the pharmacokinetics of cefepime in post-dialysis therapy. Methods Since June 2012, twelve infections were treated with post-dialysis cefepime in 9 patients on high-flux hemodialysis. The initial post-dialysis dose of cefepime was approximately 15 mg/kg. The following doses were adapted according to the trough serum levels obtained before the subsequent dialysis in order to be above the EUCAST breakpoints for susceptible organisms and above the MIC90. Residual plasma concentrations were determined before (n = 30) and after (n = 17) dialysis by liquid chromatography–mass spectrometry. Results Overall, the mean ± SD dose of cefepime was 920 ± 270 mg (14.5 ± 5.1 mg/kg), but it was significantly lower before the 48 h interval (775 ± 210 mg or 12.7 ± 4.5 mg/kg) compared to the 72 h interval (1125 ± 225 mg or 17.2 ± 4.9 mg/kg) (p 1 mg/l) with the exception of Pseudomonas aeruginosa (>8 mg/l). Cefepime concentrations were higher in anuric patients compared to those with preserved diuresis (15.6 ± 3.5 vs 9.25 ± 3.6 mg/l; p
- Published
- 2016
12. [Not Available]
- Author
-
Ould Maouloud, Hemett and Eric, Descombes
- Subjects
Purpura, Thrombotic Thrombocytopenic ,Thrombotic Microangiopathies ,Hemolytic-Uremic Syndrome ,Humans ,Female - Published
- 2015
13. Comparaison des taux de troponines cardiaques I et T mesurés chez des patients hémodialysés asymptomatiques selon différents immunodosages de dernière génération
- Author
-
Pierre-Yves Martin, Gilbert Fellay, Eric Descombes, Patrick Deleaval, and Jean-Luc Magnin
- Subjects
Gynecology ,medicine.medical_specialty ,Nephrology ,business.industry ,medicine ,business - Abstract
Resume Plusieurs etudes ont montre des taux de troponines cardiaques I (cTnI) et T (cTnT) superieurs a la norme chez un nombre significatif de patients hemodialyses sans evidence de syndrome coronarien aigu. C'est pourquoi nous avons evalue la specificite des troponines I et T dans un collectif de patients hemodialyses asymptomatiques, en utilisant des immunodosages de derniere generation. Cinquante patients en hemodialyse chronique (34 hommes), sans symptomes d'ischemie myocardique aigue, ont ete etudies. L'âge moyen etait de 64,4 ± 12,7 ans, 22 patients (44 %) avaient des antecedents de cardiopathie ischemique et 19 etaient diabetiques (38 %). Les troponines I et T ont ete mesurees avant et apres dialyse, et les resultats obtenus ont ete compares a ceux d'un groupe temoin de 30 patients hospitalises, sans insuffisance renale. Les cTnI ont ete mesurees par la methode Dimension® RxL « Improved method » (Dade Behring), les cTnT par la methode Elecsys® Assay de troisieme generation (Roche Diagnostics) et les creatines kinases (CK) par la methode Integra® (Roche Diagnostics). Les cTnI ont aussi ete mesurees simultanement par la methode utilisee auparavant dans notre hopital, ici appelee « ancienne methode » (Dimension® RxL, Dade Behring). Avec le dosage de derniere generation, un seul patient dialyse (2 %) presentait un taux de cTnI eleve (> 0,1 μg/l), contre aucun dans le groupe temoin (p = NS), alors qu'avec l'ancienne methode 11 patients (22 %) presentaient des taux predialytiques eleves (> 0,3 μg/l) (p 0,1 μg/l) ont ete retrouves chez 23 patients hemodialyses (46 %) contre aucun dans le groupe temoin (p 170 U/l) chez quatre hemodialyses (8 %) contre un patient (3,3 %) dans le groupe temoin (p = NS). Pendant la dialyse, les taux de cTnT diminuent legerement, mais de facon non significative (de 0,102 ± 0,070 a 0,085 ± 0,067 μg/l, p = NS), alors qu'il n'y a pas de changement des taux de cTnI et de CK. En conclusion, la specificite du dosage des troponines cardiaques I est significativement amelioree (de 78 a 98 %) avec la methode de dosage de derniere generation utilisee, au point d'etre similaire a celle d'un groupe temoin. De ce fait la mesure des cTnI par cette methode peut etre recommandee pour le diagnostic du syndrome coronarien aigu chez les patients hemodialyses. En revanche, les taux de troponines T restent superieurs a la norme chez une proportion importante (46 %) de patients hemodialyses asymptomatiques. D'autres etudes restent necessaires pour preciser l'origine de cette elevation.
- Published
- 2006
14. Contrast-induced acute kidney injury following iodine opacification other than by intravascular injection
- Author
-
Ould Maouloud Hemett, Tilman Perrin, Eric Descombes, and Markus Menth
- Subjects
Transplantation ,Pathology ,medicine.medical_specialty ,iodine toxicity ,business.industry ,enteroclysis ,Acute kidney injury ,chemistry.chemical_element ,Absorption (skin) ,medicine.disease ,Iodine ,acute renal failure ,Clinical Reports ,Nephrotoxicity ,acute kidney injury ,contrast-induced acute kidney injury ,Iodinated contrast ,chemistry ,Nephrology ,Toxicity ,Clinical Cases ,medicine ,In patient ,business ,Intravascular injection - Abstract
Contrast-induced acute kidney injury (CI-AKI) classically occurs following the intravascular administration of iodinated contrast medium (CM). However, some cases of iodine-induced nephrotoxicity have been reported in patients who did not receive intravascular CM, as a consequence of iodine absorption through mucosae, burned skin or interstitial tissues. Recently, we observed the first case of CI-AKI occurring after an enteroclysis without any direct intravascular injection of CM. Here, we report this case, and review other clinical situations in which renal toxicity has been reported following the non-intravascular use of iodinated compounds.
- Published
- 2012
15. Oral Postdialysis Cholecalciferol Supplementation in Patients on Maintenance Hemodialysis: A Dose-Response Approach
- Author
-
Jean-Luc Magnin, Gilbert Fellay, Benoit Fellay, Ould Maouloud Hemett, and Eric Descombes
- Subjects
musculoskeletal diseases ,Pediatrics ,medicine.medical_specialty ,Article Subject ,business.industry ,medicine.medical_treatment ,Urology ,Maintenance hemodialysis ,medicine.disease ,Target range ,lcsh:Diseases of the genitourinary system. Urology ,lcsh:RC870-923 ,vitamin D deficiency ,chemistry.chemical_compound ,chemistry ,Nephrology ,Weekly dose ,medicine ,Clinical Study ,In patient ,Hemodialysis ,Cholecalciferol ,business - Abstract
The aim of the present study was to evaluate the dose of postdialysis cholecalciferol needed to maintain the 25-hydroxyvitamin D [25(OH)D] levels in the optimal range of 75–150 nmol/L. Twenty-six patients who had low baseline 25(OH)D levels (mean27.5±14.9 nmol/L) were studied. The 25(OH)D levels were measured every 2 months for one year. During the first two months, all the patients received 2000 IU of cholecalciferol after each hemodialysis (=6000 IU/wk). Thereafter, the dose was individualized and adapted every 2 months by administering 1 to 6 cholecalciferol tablets (2000 IU each) per week (total weekly dose = 2000–12000 IU/wk). During cholecalciferol supplementation, the 25(OH)D concentrations rapidly increased from baseline to140.1±28.3 nmol/L at month 6 and95.6±20.9 nmol/L at month 12. At month twelve, 86% of the patients had 25(OH)D levels within the target range with a mean dose of5917±4106 IU/wk of cholecalciferol; however, the amount needed to maintain these levels varied widely from 0 (n=2) to 12000 IU/wk (n=5). In conclusion, postdialysis cholecalciferol prescription is quite effective in correcting vitamin D deficiency/insufficiency, but the amount of cholecalciferol needed to maintain the 25(OH)D levels within the optimal range over the long-term varies widely among patients and must be individualized.
- Published
- 2014
16. Difference in the homocysteine‐lowering effect of folic acid in haemodialysis patients with and without occlusive vascular disease
- Author
-
Olivier Boulat, Louis-Félix Bersier, Eric Descombes, and Gilbert Fellay
- Subjects
Male ,medicine.medical_specialty ,Homocysteine ,medicine.medical_treatment ,Gastroenterology ,chemistry.chemical_compound ,Folic Acid ,Renal Dialysis ,Internal medicine ,medicine ,Humans ,Prospective Studies ,Vascular Diseases ,Risk factor ,Aged ,Female ,Kidney Failure, Chronic ,Middle Aged ,Dialysis ,chemistry.chemical_classification ,Transplantation ,business.industry ,Surgery ,medicine.anatomical_structure ,chemistry ,Folic acid ,Nephrology ,Thiol ,Hemodialysis ,Multivitamin ,business ,Artery - Abstract
BACKGROUND: Hyperhomocysteinaemia has been identified as an independent cardiovascular risk factor and is found in more than 85% of patients on maintenance haemodialysis. Previous studies have shown that folic acid can lower circulating homocysteine in dialysis patients. We evaluated prospectively the effect of increasing the folic acid dosage from 1 to 6 mg per dialysis on plasma total homocysteine levels of haemodialysis patients with and without a history of occlusive vascular artery disease (OVD). METHODS: Thirty-nine stable patients on high-flux dialysis were studied. Their mean age was 63 +/-11 years and 17 (43%) had a history of OVD, either coronary and/or cerebral and/or peripheral occlusive disease. For several years prior to the study, the patients had received an oral post-dialysis multivitamin supplement including 1 mg of folic acid per dialysis. After baseline determinations, the folic acid dose was increased from 1 to 6 mg/dialysis for 3 months. RESULTS: After 3 months, plasma homocysteine had decreased significantly by approximately 23% from 31.1 +/- 12.7 to 24.5 +/- 9 micromol/l (P = 0.0005), while folic acid concentrations had increased from 6.5 +/- 2.5 to 14.4+/-2.5 microg/l (P < 0.0001). However, the decrease of homocysteine was quite different in patients with and in those without OVD. In patients with OVD, homocysteine decreased only marginally by approximately 2.5% (from 29.0 +/- 10.3 to 28.3 +/- 8.4 micromol/l, P = 0.74), whereas in patients without OVD there was a significant reduction of approximately 34% (from 32.7+/-14.4 to 21.6+/-8.6 micromol/l, P = 0.0008). Plasma homocysteine levels were reduced by > 15% in three patients (18%) in the group with OVD compared with 19 (86%) in the group without OVD (P = 0.001), and by > 30% in none of the patients (0%) in the former group compared with 13 (59%) in the latter (P = 0.001). CONCLUSIONS: These results indicate that the homocysteine-lowering effect of folic acid administration appears to be less effective in haemodialysis patients having occlusive vascular disease than in those without evidence of such disease.
- Published
- 2001
17. REPEATED TRANSIENT ANURIA FOLLOWING LOSARTAN ADMINISTRATION IN A PATIENT WITH A SOLITARY KIDNEY
- Author
-
Eric Descombes, Gilbert Fellay, Claude Regamey, and Jacques-Olivier Maillard
- Subjects
Male ,medicine.medical_specialty ,Angiotensin II receptor antagonist ,Anuria ,urologic and male genital diseases ,Critical Care and Intensive Care Medicine ,Renal artery stenosis ,Losartan ,Renin-Angiotensin System ,Angiotensin Receptor Antagonists ,Internal medicine ,medicine ,Humans ,Antihypertensive Agents ,Aged ,business.industry ,General Medicine ,medicine.disease ,Angiotensin II ,Surgery ,Hypertension, Renovascular ,Blood pressure ,Nephrology ,Heart failure ,Cardiology ,Kidney Failure, Chronic ,medicine.symptom ,business ,medicine.drug ,Kidney disease - Abstract
We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration. He was hospitalized for a myocardial infarction with pulmonary edema, treated with high-dose diuretics. Due to severe systolic dysfunction losartan was prescribed. Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion. One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient anuria lasting 10 hours. During these two episodes, his blood pressure diminished but no severe hypotension was noted. Ultimately, an arteriography showed a 70-80% renal artery stenosis. In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS). Under such conditions, angiotensin II receptor blockade by losartan probably induced a critical fall in glomerular filtration pressure. This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting.
- Published
- 2001
18. 3rd Basic Multidisciplinary Hemodialysis Access Course
- Author
-
Tsuneki Imai, R. Zanchi, T. Lopez, Toshihide Naganuma, Robert W. Nette, Hiromichi Suzuki, D. Mostacci, Yoshinari Tsuruta, S. Savoldi, M.A. Lauria, Tsuneo Takenaka, C.J. Holmes, C. Bagnato, Robert Zietse, V. Gaudiano, Gilbert Fellay, Harmen P. Krepel, Shinichi Hirose, N. Lameire, Andrew Davenport, Vincenzo Bellizzi, G. Ferlan, Eric Descombes, F. Iannuzziello, Helmut Schiffl, A. Bombini, W. Kubey, F. Bianco, M.A. Lotito, P. Marino, Kenji Kobayashi, Yuko Kakiya, Yoshihiro Matsumoto, Taketoshi Kishimoto, G. Galli, S. Vianello, R. Vanholder, B. Di Iorio, Michio Murata, G. Plastino, Biagio Di Iorio, G. Santarsia, V. Terracciano, Yoshitsugu Tsuchiya, Kazunobu Sugimura, V. Bellizzi, G. Marinaro, P. Keshaviah, R. Biscione, P. Straka, Yoshiaki Itaya, Shigeko Hara, François Perriard, André Jutzet, R. Molinari, G. Panzetta, M. Procida, A. Dal Moro, F. Casino, Peter Stenvinkel, A. Caputo, Emin Akçahüseyin, M. Ianche, E. Vidi, P. Carretta, V. Valente, D. Sanicandro, Izumi Amano, Chikako Okada, Takeshi Sugimura, P. Klein, P. Cicinato, and Willem Weimar
- Subjects
medicine.medical_specialty ,Nephrology ,business.industry ,Multidisciplinary approach ,medicine ,Hematology ,General Medicine ,Intensive care medicine ,business ,Hemodialysis access - Published
- 2000
19. 18th Annual Meeting of the International Society of Blood Purification
- Author
-
Shigeko Hara, V. Valente, Izumi Amano, André Jutzet, Tsuneo Takenaka, M. Ianche, M.A. Lauria, Willem Weimar, Tsuneki Imai, G. Panzetta, Yoshiaki Itaya, D. Mostacci, D. Sanicandro, Harmen P. Krepel, R. Zanchi, M. Procida, Kenji Kobayashi, S. Savoldi, E. Vidi, A. Dal Moro, Toshihide Naganuma, Shinichi Hirose, F. Casino, C. Bagnato, N. Lameire, Andrew Davenport, P. Carretta, R. Molinari, A. Bombini, Gilbert Fellay, François Perriard, Taketoshi Kishimoto, G. Ferlan, Peter Stenvinkel, Biagio Di Iorio, F. Iannuzziello, G. Marinaro, Chikako Okada, A. Caputo, Hiromichi Suzuki, Yoshitsugu Tsuchiya, V. Bellizzi, G. Galli, Emin Akçahüseyin, W. Kubey, Yoshinari Tsuruta, S. Vianello, Robert Zietse, Kazunobu Sugimura, P. Klein, V. Gaudiano, V. Terracciano, G. Santarsia, G. Plastino, P. Cicinato, R. Vanholder, B. Di Iorio, P. Keshaviah, R. Biscione, C.J. Holmes, Yoshihiro Matsumoto, Michio Murata, Vincenzo Bellizzi, Eric Descombes, T. Lopez, Robert W. Nette, Takeshi Sugimura, Helmut Schiffl, M.A. Lotito, P. Marino, F. Bianco, Yuko Kakiya, and P. Straka
- Subjects
medicine.medical_specialty ,Nephrology ,business.industry ,Blood purification ,Medicine ,Physiology ,Hematology ,General Medicine ,business ,Intensive care medicine - Published
- 2000
20. Diffusion Kinetics in Blood during Haemodialysis and in vivo Clearance of Inorganic Phosphate
- Author
-
Eric Descombes, André Jutzet, François Perriard, and Gilbert Fellay
- Subjects
Erythrocytes ,Time Factors ,Chromatography ,Chemistry ,medicine.medical_treatment ,Diffusion ,Kinetics ,Hematology ,General Medicine ,Phosphate ,Phosphates ,Red blood cell ,chemistry.chemical_compound ,Blood ,medicine.anatomical_structure ,Renal Dialysis ,Nephrology ,In vivo ,medicine ,Humans ,Hemodialysis ,Dialysis (biochemistry) ,Blood drawing - Abstract
Contradictory data are reported in the literature concerning the diffusion kinetics of inorganic phosphates (iPh) between red blood cells and plasma during haemodialysis. Accordingly, we performed mass balance and equilibration studies to analyze the diffusion kinetics of iPh in vivo and in vitro. Mass balance analysis shows that iPh is only cleared from the plasma volume and thus that it practically does not diffuse from red blood cells to plasma during the short time lapse of blood transit through the haemodialyzer. In vitro equilibration studies of blood drawn at the filter outlet show that at room temperature there is a slow, limited, and almost linear net efflux of iPh during the 4 h that follow blood drawing. Our results point out: (1) that the in vivo clearance of iPh should be exclusively determined as plasma clearance, and (2) that for accurate clearance determinations the iPh concentrations should be measured in blood samples centrifuged within at most 1 h after blood drawing. Whole-blood clearance determinations – as well as the in vitro dialyzer data – largely overestimate (>30%) the real in vivo dialyzer performance.
- Published
- 2000
21. Water‐Soluble Vitamin Levels in Patients Undergoing High‐Flux Hemodialysis and Receiving Long‐Term Oral Postdialysis Vitamin Supplementation
- Author
-
Olivier Boulat, Eric Descombes, François Perriard, and Gilbert Fellay
- Subjects
Adult ,Male ,Vitamin ,medicine.medical_specialty ,Erythrocytes ,Homocysteine ,Riboflavin ,Biomedical Engineering ,Medicine (miscellaneous) ,Bioengineering ,Ascorbic Acid ,Gastroenterology ,Biomaterials ,chemistry.chemical_compound ,Folic Acid ,Renal Dialysis ,Internal medicine ,Humans ,Medicine ,Thiamine ,Pyridoxine Hydrochloride ,Chromatography, High Pressure Liquid ,Aged ,Aged, 80 and over ,Analysis of Variance ,business.industry ,Oxalic Acid ,Pyridoxine ,Vitamins ,General Medicine ,Middle Aged ,Ascorbic acid ,Cross-Sectional Studies ,chemistry ,Water-Soluble Vitamin ,Female ,business ,Multivitamin ,medicine.drug - Abstract
The prescription of multivitamin supplements for dialysis patients is routine practice, but the doses prescribed differ greatly from one dialysis center to another. Few data are available concerning long-term vitamin supplementation and its effects on patients either on high-flux hemodialysis or receiving postdialysis supplementation. For several years, we have systematically prescribed to our patients an oral postdialysis multivitamin supplement containing thiamine hydrochloride 100 mg, riboflavin 20 mg, pyridoxine hydrochloride 50 mg, folic acid 6 mg, and ascorbic acid 500 mg. The aim of this study was to perform a cross-sectional long-term evaluation of the vitamin levels in patients who received this vitamin supplement for at least 12 months. We also were interested in investigating the plasma oxalic acid and total homocysteine levels associated with the long-term prescription of these vitamin supplements. Thirty-three patients on high-flux dialysis were studied. Vitamin levels and/or vitamin-dependent enzymatic activities were within the normal range (N) in all patients. The mean results (+/-SD) were plasma ascorbic acid 13.6 +/- 6.4 mg/L (N4), plasma folate 14.1 +/- 1.1 microg/L (N3), for vitamin B1, alpha-ETK 1.02 +/- 0.02 (N1.18) and ETKo 100 +/- 13 U/L (N70), for vitamin B2, alpha-EGR 1.00 +/- 0.07 (N1.52) and EGRo 1282 +/- 213 U/L (N672), and for vitamin B6, alpha-EGOT 1.34 +/- 0.10 (N1.8) and EGOTo 380 +/- 84 U/L (N228). Plasma oxalic acid was higher than normal in all patients (mean = 61 +/- 15 micromol/L, N33). However, all patients had oxalic acid levels within the range reported in the literature for patients not taking extra ascorbic acid. Mean total homocysteine was 24 +/- 8 micromol/L with only 4 patients (12%) having normal levels (N15). In conclusion, the postdialysis supplement given provides adequate vitamin levels in almost all patients in the long term. Postdialysis prescription allows an optimal compliance with the treatment, is well accepted by the patients, and is cost-effective.
- Published
- 2000
22. Urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) and contrast-induced acute kidney injury after coronary angiogram
- Author
-
Mario Togni, Stéphane Cook, Gérard Baeriswyl, Daniel Hayoz, Magali Gachet, Valérie Stolt, Ould Maouloud Hemett, Jean-Luc Magnin, Tilman Perrin, Eric Descombes, Jean-Jacques Goy, and Jean-Christophe Stauffer
- Subjects
Male ,medicine.medical_specialty ,Percutaneous ,Urinary system ,Urology ,Contrast Media ,Lipocalin ,Coronary Angiography ,Cohort Studies ,chemistry.chemical_compound ,Lipocalin-2 ,Proto-Oncogene Proteins ,Medicine ,Humans ,Aged ,Creatinine ,Dose-Response Relationship, Drug ,business.industry ,Acute kidney injury ,General Medicine ,Acute Kidney Injury ,Middle Aged ,medicine.disease ,Lipocalins ,Iopamidol ,Contrast medium ,Early Diagnosis ,chemistry ,Cohort ,Female ,business ,Biomarkers ,Cohort study ,Acute-Phase Proteins - Abstract
QUESTIONS UNDER STUDY Diagnosis of acute kidney injury (AKI) relies on measurement of serum creatinine (SCr). SCr is a late marker of impaired renal function. Urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) has given encouraging results for an early and sensitive detection of AKI. This cohort study was conducted (1) to assess the value of uNGAL as early marker of contrast-induced AKI (CI-AKI) in unselected patients undergoing percutaneous coronary procedure (PCP) and (2) to investigate whether uNGAL levels correlate with the volume of contrast medium (CM) used during the procedure. METHODS We enrolled 244 consecutive adult patients undergoing PCP done with the low-osmolar CM Iomeprolum (median volume of CM 122 [88-168] ml per procedure). uNGAL was measured at its peak with a standardised clinical laboratory platform (ARCHITECT uNGAL assay, Abbott). RESULTS Overall, the post-PCP uNGAL levels were extremely low in our cohort with a median value of 7.7 [4.0-14.5] ng/ml (N ≤132 ng/ml). Twenty-five (10%) patients developed CI-AKI according to the classical diagnostic criteria (≥25% or ≥44.2 µmol/l increase in SCr) and 8 (3.3%) patients according to the AKIN criteria. Regardless of the definition considered, uNGAL levels did not significantly differ in patients with or without CI-AKI. Similarly, we found no significant correlation between the volume of CM used and the post-PCP uNGAL levels (r = -0.11). CONCLUSIONS In a large cohort of unselected adult patients, uNGAL measured four to six hours after PCP was ineffective to predict the risk of CI-AKI and did not correlate with the volume of CM used during the procedure.
- Published
- 2013
23. TCT-137 Is Urinary Neutrophil Gelatinase-Associated Lipocalin the 'Renal Troponin' in Invasive Cardiology?
- Author
-
Stéphanie Gobet, Stéphane Cook, Jean-Christophe Stauffer, Mario Togni, Magali Gachet, Jean-Luc Magnin, Valérie Stolt, Ould Maouloud Hemett, Tilman Perrin, Eric Descombes, Daniel Hayoz, Jean-Jacques Goy, and Gérard Baeriswyl
- Subjects
Neutrophil gelatinase-associated lipocalin ,medicine.medical_specialty ,biology ,business.industry ,Urinary system ,cardiovascular system ,biology.protein ,Urology ,Medicine ,Invasive cardiology ,business ,Cardiology and Cardiovascular Medicine ,Troponin - Published
- 2012
- Full Text
- View/download PDF
24. Contrast-induced nephropathy in invasive cardiology
- Author
-
Stéphane Cook, Tilman Perrin, and Eric Descombes
- Subjects
medicine.medical_specialty ,Urinary system ,medicine.medical_treatment ,Urology ,Contrast-induced nephropathy ,Contrast Media ,Renal function ,urologic and male genital diseases ,Nephropathy ,chemistry.chemical_compound ,Risk Factors ,Humans ,Medicine ,Clinical significance ,Angioplasty, Balloon, Coronary ,Creatinine ,business.industry ,Incidence ,Acute kidney injury ,Percutaneous coronary intervention ,General Medicine ,Acute Kidney Injury ,Prognosis ,medicine.disease ,female genital diseases and pregnancy complications ,Surgery ,Treatment Outcome ,chemistry ,business ,Biomarkers ,Iodine - Abstract
Contrast-induced nephropathy (CIN) is an acute renal injury due to the renal toxicity of iodinated contrast media. It is classically defined as a relative (≥25%) or absolute (≥0.5 mg/dl; 44 μmol/l) increase in serum creatinine from baseline value. CIN accounts for 10 to 15% of hospital-acquired acute renal failure and may rarely lead to irreversible renal function loss. Following percutaneous coronary intervention, reported incidence of CIN varies between 0 to more than 20%, depending on the prevalence of risk factors and used definition. Nowadays, the diagnosis of CIN relays on serum creatinine monitoring, although it is a late marker of acute kidney injury. Given the expanding number of percutaneous coronary interventions made in outpatient settings and the morbidity and mortality associated with CIN, early detection of CIN is of utmost clinical relevance. Several plasmatic and urinary biomarkers have been studied in that view, with plasmatic cystatine-C and urinary NGAL being the most promising. As no treatment specifically targets CIN once it develops, the main goal for clinicians remains prevention, with hydration status optimisation being the only proven strategy to date. Here, we will review the recent evidence concerning CIN, its incidence, proposed early diagnostic biomarkers, as well as its treatment and prognostic implication.
- Published
- 2012
25. Urea kinetic modeling: An in vitro and in vivo comparative study
- Author
-
Jean-Pierre Gabriel, Gilbert Fellay, and Eric Descombes
- Subjects
Male ,Chromatography ,Kinetic model ,Chemistry ,medicine.medical_treatment ,Body water ,Middle Aged ,Models, Biological ,In vitro ,Kinetics ,chemistry.chemical_compound ,Biochemistry ,Renal Dialysis ,Nephrology ,In vivo ,Dialysis Solutions ,Urea ,medicine ,Humans ,Female ,Hemodialysis ,Dialysis (biochemistry) ,Mathematical Computing ,Clearance - Abstract
Urea kinetic modeling: An in vitro and in vivo comparative study. The urea kinetic model (UK) and the direct dialysis quantification method based on dialysate collection (DDQ) were used to determine the urea distribution volume (V) identified with the total body water and the urea generation rate (G) for different dialysis times, both in vivo during short hemodialysis (N = 20) and in vitro using an experimental single-pool urea system (N = 10). Both UK and DDQ allowed a satisfactory in vitro estimation of V and G for all dialysis times. On the other hand in vivo V and G estimations by both methods showed an increase of more than 50% between the determinations performed after 30 minutes of dialysis and at the end of dialysis. Our theoretical analysis shows that the in vivo changes of V are compatible with those expected for a two-compartment system in which one compartment is cleared faster than the other. Furthermore, given that urea is allowed to equilibrate in the body at the end of dialysis, DDQ permits an accurate estimate of V, G and PCR even for short hemodialysis, which UK does not.
- Published
- 1994
26. [Hematuria: which algorithm for an effective diagnostic strategy?]
- Author
-
Ould Maouloud, Hemett, Eric, Descombes, Joseph, Eigenmann, Daniel, Betticher, and Daniel, Hayoz
- Subjects
Adult ,Diagnosis, Differential ,Nephrology ,Urology ,Prevalence ,Humans ,Kidney Diseases ,Algorithms ,Hematuria - Abstract
Microscopic hematuria is common in medical practice; its prevalence in the adult population varies between 2.5 and 13%. Currently available data are insufficient to determine an algorithm based on evidence of the most effective diagnostic strategy of hematuria. Avoid invasive tests for the patient and expensive for the community, determine whether the hematuria of glomerular origin or not, facilitate the clinician referral to a nephrologist or urologist for the etiological diagnosis, should be the basic principles of any approach to develop such an algorithm. We try to answer on this question in this article.
- Published
- 2010
27. Cardiac findings in asymptomatic chronic hemodialysis patients with persistently elevated cardiac troponin I levels
- Author
-
Jean-Luc Magnin, Ioannis Katerinis, Eric Descombes, and Q. V. Nguyen
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,macromolecular substances ,Coronary Artery Disease ,Critical Care and Intensive Care Medicine ,Coronary Angiography ,Kidney Function Tests ,Asymptomatic ,Risk Assessment ,Sensitivity and Specificity ,Severity of Illness Index ,Coronary artery disease ,Cohort Studies ,Age Distribution ,Troponin T ,Reference Values ,Renal Dialysis ,Internal medicine ,Troponin I ,medicine ,Humans ,Mass Screening ,cardiovascular diseases ,Myocardial infarction ,Sex Distribution ,Mass screening ,Dialysis ,Aged ,business.industry ,Incidence ,General Medicine ,Middle Aged ,medicine.disease ,Long-Term Care ,Echocardiography, Doppler ,Nephrology ,Heart failure ,cardiovascular system ,Cardiology ,Kidney Failure, Chronic ,Female ,Hemodialysis ,medicine.symptom ,business ,Biomarkers ,Follow-Up Studies - Abstract
Background. The prevalence and significance of higher than normal cardiac troponin I (cTnI) levels in asymptomatic chronic hemodialysis (HD) patients remains a source of discussion. The aim of the present study was to evaluate the prevalence of higher than normal cTnI levels in asymptomatic HD patients, as determined by the last generation of immunoassay, and to perform further cardiological investigations in those patients with persistently elevated cTnI levels. Methods. All chronic HD patients in our center who had exhibited no symptoms of coronary artery disease (CAD) during the previous four weeks were screened. cTnI levels were determined before dialysis in all patients using the last generation AccuTnI™ assay (UniCel DxI 800, Beckman Coulter). The cTnI levels of those patients with elevated cTnI at the screening evaluation were then measured monthly for six months. We were thus able to identify a group of patients with persistently elevated cTnI levels (> 3 consecutive months) who subsequently underwent cardiac echography and dipyridamole-exercise (D-E) thallium testing. If stress myocardial ischemia was detected, a coronary angiography was then performed. Results. Fifty patients (32 males) were included: mean age 62.8 ± 13.6 years, 20 (40%) with a history of CAD, and 21 (42%) diabetic. At the initial screening, the mean cTnI concentration was 0.05 ± 0.06 μg/L and the cTnI levels were higher than normal (> 0.09 μg/L) in six patients (12%). In the follow-up, the cTnI normalized immediately in two patients but remained persistently elevated (range, 0.10–0.48 μg/L) in four (8%). These four patients (all males, one diabetic) had a mean age of 70.2 ± 6.6 years, and all had heart failure with a history of severe CAD with previous myocardial infarction (n = 4), coronary stenting (n = 3), and/or bypass (n = 2). D-E thallium imaging showed reversible myocardial ischemia in all. The stress ischemia involved one to four cardiac segments and was slight to moderate in three patients and severe in the diabetic patient. A coronary angiogram was performed in all patients, and showed lesions of variable severity: severe three-vessel CAD with severe systolic dysfunction in two patients (including the diabetic), and non-critical/ peripheral coronary stenosis in the other two. Conclusions. Among the asymptomatic HD patients in our center, we identified four (8%) with persistently elevated cTnI levels, as determined using the last generation AccuTnI™ assay. All of them had a history of severe CAD with heart failure and exhibited reversible myocardial ischemia upon D-E thallium imaging; coronary angiography revealed coronary lesions of variable severity. Overall, our data indicate that persistent low-grade cTnI elevation occurs in HD patients having longstanding severe cardiac disease, but, from our data, it is difficult to reach a conclusion as to the best clinical approach for this group of patients.
- Published
- 2008
28. Penile necrosis in a haemodialysis patient: a rare manifestation of cholesterol crystal embolism
- Author
-
Gilbert Fellay, Eric Descombes, Pablo Mondragon, and Jurg Bollmann
- Subjects
Male ,medicine.medical_specialty ,Necrosis ,medicine.medical_treatment ,Fatal Outcome ,Renal Dialysis ,medicine ,Humans ,Aged ,Embolism, Cholesterol ,Uremia ,Transplantation ,Vascular disease ,business.industry ,medicine.disease ,Surgery ,Arterioles ,medicine.anatomical_structure ,Embolism ,Nephrology ,Hemodialysis ,medicine.symptom ,Crystallization ,Complication ,business ,Penis ,Kidney disease ,Artery - Published
- 1998
29. Adult hemolytic-uremic syndrome associated with urosepsis due to Shigatoxin-producing Escherichia coli O138:H
- Author
-
Q. V. Nguyen, Claude Regamey, Christian Chuard, Lucile Hochstrasser, Herbert Hächler, and Eric Descombes
- Subjects
Nephrology ,Hemolytic anemia ,Male ,medicine.medical_specialty ,Resuscitation ,Sus scrofa ,urologic and male genital diseases ,Critical Care and Intensive Care Medicine ,medicine.disease_cause ,Gastroenterology ,Shiga Toxin ,Internal medicine ,medicine ,Escherichia coli ,Animals ,Humans ,Escherichia coli Infections ,biology ,Vascular disease ,business.industry ,Shiga toxin ,General Medicine ,Middle Aged ,medicine.disease ,biology.organism_classification ,Enterobacteriaceae ,female genital diseases and pregnancy complications ,Surgery ,Hemolytic-Uremic Syndrome ,Urinary Tract Infections ,biology.protein ,business ,Kidney disease - Abstract
We report the case of a 62-year-old man without prodromal symptoms who developed a hemolytic-uremic syndrome (HUS) one week after the diagnosis of an acute bacteremic urinary infection (UTI). In this patient, the E. coli isolated in blood cultures was a non-O157:H7 Shigatoxin-producing strain that could subsequently be identified as O138:H-. This is a strain that is normally found in pigs and that has never been isolated in humans previously. UTI-related HUS is a rare event, as until now, only 14 pediatric and 3 adult cases have been reported. Indeed, this new case, besides its interesting microbiological aspects, should heighten our awareness of UTI-related HUS as a rare but real condition, not only in young children but also in adult patients. This should emphasize the necessity to search actively for other sources of Shigatoxin-producing E. coli in patients presenting with HUS without gastrointestinal symptoms.
- Published
- 2007
30. [Differences in cardiac troponin I and T levels measured in asymptomatic hemodialysis patients with last generation immunoassays]
- Author
-
Patrick, Deléaval, Eric, Descombes, Jean-Luc, Magnin, Pierre-Yves, Martin, and Gilbert, Fellay
- Subjects
Immunoassay ,Male ,Troponin T ,Renal Dialysis ,Troponin I ,Humans ,Female ,Middle Aged ,Aged - Abstract
Previous studies reported cardiac troponin I (cTnI) and T (cTnT) levels to be higher than normal in a significant proportion of asymptomatic chronic hemodialysis (HD) patients without evidence of acute myocardial injury. We have therefore evaluated in such patients the accuracy of cTnI and cTnT determinations measured with last generation assays. Fifty chronic HD patients (34 males) without symptoms of acute myocardial ischemia were studied. Their mean age (+/-SD) was 64.4+/-12.7 years, 22 patients (44%) had an history of cardiac ischemic disease and 19 (38%) were diabetics. Serum cardiac markers were measured with last generation assays before and after a single HD session and in a control group including 30 hospitalized patients without renal failure. The cTnI were determined with Dimension RxL "Improved method" assay (Dade Behring), the cTnT with Elecys "Third generation" assay (Roche Diagnostics) and the creatine kinase (CK) with Integra (Roche Diagnostics). The cTnI were also simultaneously determined with the assay previously used at our institution (Dimension RxL, Dade Behring), indicated as old-method-cTnI. With the last generation assay only 1 patient (2%) had elevated cTnI (0.1 microg/l) in the study group compared to none in the control group (P=NS). Instead, with the old-method-cTnI assay 11 patients (22%) had elevated (0.3 microg/l) predialysis cTnI levels (P0.01 compared to the "Improved method" assay). The predialysis cTnT levels were higher than normal (0.1 microg/l) in 23 patients (46%), compared to none in the control group (P0.01). The CK levels were elevated (170 IU/L) in 4 dialysis patients (8%) compared to one (3,3%) in the control group (P=NS). The cTnT levels slightly but non-significantly diminished during dialysis (from 0.102+/-0.070 to 0.085+/-0.067 mug/l, P=NS), while in the same time no changes were observed for cTnI and CK levels. In conclusion, the specificity of cTnI determinations in HD patients is greatly improved by the last generation assay (from 78 to 98%), and is actually similar to that observed in a population with normal renal function. Therefore cTnI, determined with the last generation assay used in the present study, can be reliably used for the diagnosis of acute coronary syndromes in HD patients. Instead, cTnT levels remain higher than normal in a significant proportion of asymptomatic HD patients (46%) and the reasons for this fact need further investigations.
- Published
- 2005
31. Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure
- Author
-
Pierre Monney, Q. V. Nguyen, Henri Perroud, and Eric Descombes
- Subjects
Parathyroidectomy ,medicine.medical_specialty ,Hypercalcaemia ,medicine.medical_treatment ,Anti-Inflammatory Agents ,Pamidronate ,Anti-Inflammatory Agents/therapeutic use ,C-Reactive Protein/analysis ,Calciphylaxis/drug therapy ,Calciphylaxis/etiology ,Diphosphonates/therapeutic use ,Female ,Humans ,Infusions, Intravenous ,Kidney Failure, Chronic/complications ,Middle Aged ,Gastroenterology ,Internal medicine ,medicine ,Transplantation ,Calciphylaxis ,Diphosphonates ,business.industry ,Pamidronic acid ,Bisphosphonate ,medicine.disease ,Surgery ,C-Reactive Protein ,Nephrology ,Tumoral calcinosis ,Kidney Failure, Chronic ,Hemodialysis ,business ,Kidney disease ,medicine.drug - Abstract
Calciphylaxis, also called calcific uraemic arteriolopathy, is a rare disease characterized by medial calcification of the small arteries and ischaemia of the subcutaneous tissue, often leading to necrosis of subcutaneous fat and skin. It affects mainly women with chronic renal insufficiency and/or obesity. According to recent studies, calciphylaxis seems to occur more frequently than previously believed, with an incidence of 1% per year [1] and a prevalence of 4% in dialysis patients [2]. The pathogenesis of calciphylaxis is poorly understood and its treatment is largely empirical and somewhat controversial. Recent studies have emphasized the crucial role of a multidisciplinary therapeutic approach focusing on the correction of the underlying abnormalities of the calcium and phosphorus plasma concentrations (using non-calcium-containing phosphate binders), local wound care with debridement of necrotic tissues and aggressive treatment of infectious complications [3]. The utility of parathyroidectomy, corticoid therapy and hyperbaric oxygen therapy remains controversial. However, despite intensive combined treatments, the prognosis of calciphylaxis remains poor: the overall 1 year survival is 45% and the 5 year survival is 35%, with a relative risk of death of 8.5 compared with other dialysis patients [4]. Bisphosphonates have a powerful inhibitory effect on osteoclast activity and bone resorption and are largely used in the treatment of osteoporosis, tumoral hypercalcaemia and Paget’s disease. Some previous studies have shown that bisphosphonates also have beneficial effects on the evolution of experimental calciphylaxis [5,6] and tumoral calcinosis with systemic inflammatory response [7]. According to these latter observations, we decided to treat a woman with chronic renal failure and rapidly worsening calciphylaxis with pamidronate. This treatment brought a spectacular and rapid improvement of the patient’s clinical condition and a rapid decrease of the inflammatory syndrome. We report this case, which is, to our knowledge, the first one in which a bisphosphonate has been used to treat a patient with calciphylaxis.
- Published
- 2004
32. End-stage renal failure after irbesartan prescription in a diabetic patient with previously stable chronic renal insufficiency
- Author
-
Gilbert Fellay and Eric Descombes
- Subjects
Male ,medicine.medical_specialty ,Captopril ,medicine.medical_treatment ,Urology ,Renal function ,Tetrazoles ,urologic and male genital diseases ,Critical Care and Intensive Care Medicine ,Renal artery stenosis ,Angiotensin Receptor Antagonists ,Irbesartan ,Diabetes mellitus ,medicine ,Humans ,Diabetic Nephropathies ,Antihypertensive Agents ,Aged ,business.industry ,Biphenyl Compounds ,General Medicine ,medicine.disease ,Angiotensin II ,Surgery ,Nephrology ,Hypertension ,Kidney Failure, Chronic ,Hemodialysis ,business ,medicine.drug ,Kidney disease - Abstract
We report the case of a 78-year-old hypertensive diabetic patient without evidence of renal artery stenosis who had moderate chronic renal insufficiency, which had been stable for several years under low-dose captopril therapy, and who rapidly developed acute renal failure when irbesartan was prescribed. Unfortunately the medication was not stopped promptly and the patient never recovered his basal renal function and had to undergo chronic hemodialysis. This observation emphasizes the importance of a careful monitoring of renal function in patients receiving angiotensin II receptor antagonists.
- Published
- 2000
33. Improved response to erythropoietin therapy with long-term continuous iron supplementation
- Author
-
Gilbert Fellay and Eric Descombes
- Subjects
Ferric Oxide, Saccharated ,Male ,medicine.medical_specialty ,Iron Overload ,Anemia, Iron-Deficiency ,business.industry ,Iron ,Middle Aged ,Ferric Compounds ,Recombinant Proteins ,Term (time) ,Glucaric Acid ,Hemoglobins ,Renal Dialysis ,Ferritins ,Medicine ,Humans ,Kidney Failure, Chronic ,Female ,business ,Intensive care medicine ,Erythropoietin - Published
- 2000
34. Renal vascular lesions in lupus nephritis
- Author
-
Jean-Pierre Grünfeld, Dominique Droz, Eric Descombes, Philippe Lesavre, and Ludovic Drouet
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Thrombotic microangiopathy ,Time Factors ,Biopsy ,Kidney Glomerulus ,Lupus nephritis ,Immunoglobulins ,Lesion ,Medicine ,Humans ,Vascular Diseases ,Retrospective Studies ,Lupus anticoagulant ,Systemic lupus erythematosus ,medicine.diagnostic_test ,business.industry ,General Medicine ,medicine.disease ,Lupus Nephritis ,Microscopy, Fluorescence ,Female ,medicine.symptom ,business ,Vasculitis ,Nephritis ,Follow-Up Studies - Abstract
We retrospectively studied the prevalence, histologic features, clinical correlations, and long-term outcome of the intrarenal vascular lesions of lupus nephritis (LN) in a series of 169 renal biopsies performed between 1980 and 1994 in 132 patients with systemic lupus erythematosus. The most common vascular lesions were nonspecific sclerotic changes, found in 37% of the biopsies (24% if only the cases with moderate to severe changes are considered). The other common vascular lesions were "immunoglobulin microvascular casts," found in 24% of the biopsies. Vasculitis and thrombotic microangiopathy were rare lesions and were seen in only 4 (2.4%) and 1 (0.6%) cases, respectively. Isolated sclerotic vascular changes were present in biopsies from older patients with a longer duration of LN, compared with the group with no vascular lesions, and were associated with a significantly higher prevalence of hypertension. Overall, however, the long-term renal and patient survival of this group did not differ significantly from that of the patients without vascular changes. Immunoglobulin microvascular casts (IMCs) ("lupus vasculopathy") were characterized by the presence of immunoglobulin deposition within the glomerular capillaries and small arterioles. In the present study we extensively investigated the morphologic and immunologic features of this lesion. The lesions were notable for the absence of endothelial or parietal vascular lesions and of fibrin, platelets, and leukocytes, which indicates that thrombosis is not involved in the vascular obstruction. According to our data immunoglobulin precipitation in the microvasculature seems to play a central role in the pathogenesis of this lesion, which is why we propose the term "immunoglobulin microvascular casts." In general, IMCs were associated with the most severe and active forms of diffuse proliferative lupus nephritis (World Health Organization [WHO] class IV). However our data show that, in contrast to previous studies, the long-term outcome of patients with IMCs is not worse than that of other patients with class IV LN. It may even be somewhat better, suggesting that this type of lesion may reverse with immunosuppressive therapy. In addition, we did not find any association between the presence of IMCs and the lupus anticoagulant, IgG anticardiolipin antibodies, or extrarenal vascular manifestations. Concerning vasculitis and thrombotic microangiopathy, our results confirm that their occurrence is quite rare in-lupus nephritis. The outcome of our 4 patients with vasculitis was not particularly poor, which could be related to early and/or aggressive treatment. Taken as a whole, our data confirm that the presence of active and severe forms of diffuse proliferative LN (WHO class IV) carries a worse prognosis compared with the other forms of LN. In our study, and in agreement with previous reports (23), the long-term renal survival of patients with class IV LN was significantly worse than that of patients with other forms of LN, with a 10-year renal survival of 70% compared with 85%, respectively. However our data do not support the conclusions of some previous studies that the presence of intrarenal vascular lesions is a marker of poor renal prognosis in lupus nephritis. More precisely, our data show that the somewhat poorer renal outcome observed in patients with IMCs is related to the fact that in most cases these lesions are associated with class IV lupus nephritis, and not related to the presence of the vascular lesion per se.
- Published
- 1997
35. Water soluble vitamins in chronic hemodialysis patients and need for supplementation
- Author
-
Gilbert Fellay, Alfred B. Hanck, and Eric Descombes
- Subjects
Vitamin ,Adult ,Male ,medicine.medical_specialty ,Erythrocytes ,Adolescent ,Biotin ,Riboflavin ,Ascorbic Acid ,Gastroenterology ,chemistry.chemical_compound ,Folic Acid ,Renal Dialysis ,Internal medicine ,Medicine ,Humans ,Vitamin B12 ,Pyridoxine Hydrochloride ,Aged ,business.industry ,Vitamins ,Middle Aged ,Ascorbic acid ,Vitamin B 12 ,Endocrinology ,chemistry ,Nephrology ,Vitamin B Complex ,Transketolase activity ,Water-Soluble Vitamin ,Thiamine ,Female ,Transketolase ,business - Abstract
Water soluble vitamins in chronic hemodialysis patients and need for supplementation. Forty-three patients on chronic hemodialysis who before the present study had only received a low-dose supplement of folic and ascorbic acid were studied prospectively for one year. After baseline values were obtained in month one, increasing doses of postdialysis vitamin supplements were prescribed for the vitamins which were found to be insufficient in order to determine the minimal amount of oral postdialysis supplement necessary to normalize vitamin levels. According to our results no systematic supplement was indicated for biotin, riboflavin or vitamin B12. For folic acid and vitamin C, supplementation with lower doses than those prescribed in many dialysis units allowed optimal vitamin levels in the majority of patients; 2 to 3 mg/week (300 to 400 µg/day) of folic acid and of 1000 to 1500 mg/week (150 to 200 mg/day) of vitamin C was considered sufficient. A severe pyridoxine deficiency was present in most (> 80%) unsupplemented patients, either as judged by pyridoxal-5-phosphate determinations in plasma or determination of specific enzyme activation in erythrocytes (EGOTo and α-EGOT); a postdialysis supplement of at least 100 to 150 mg/week of pyridoxine hydrochloride (> 15 to 20 mg/day) corrects this deficiency. The activity of the thiamine-dependent enzyme transketolase in erythrocytes (ETKo) was insufficient in 35% and marginal in 21% of the patients, while whole blood thiamine determined simultaneously in 10 of the ETKo-deficient patients was within the normal range. These results suggest that in uremia insufficient transketolase activity may be related to inhibition of the enzymatic system rather than to true vitamin deficiency. On a long-term basis a supplement of 200 to 300 mg/week of thiamine hydrochloride (30 to 45 mg/day) restored ETKo to satisfactory levels in most patients; whether this supplement is to be recommended warrants further studies.
- Published
- 1993
36. Etiology-based classification of hemolytic uremic syndrome/thrombotic thrombocytopenic purpura. What about hemolytic uremic syndrome associated with urinary tract infections?
- Author
-
Eric Descombes and Q. V. Nguyen
- Subjects
Pediatrics ,medicine.medical_specialty ,business.industry ,Urinary system ,Thrombotic thrombocytopenic purpura ,urologic and male genital diseases ,medicine.disease ,Dermatology ,female genital diseases and pregnancy complications ,Nephrology ,hemic and lymphatic diseases ,Etiology ,Medicine ,business - Published
- 2007
37. Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure.
- Author
-
Pierre Monney, Quan-Vinh Nguyen, Henri Perroud, and Eric Descombes
- Published
- 2004
- Full Text
- View/download PDF
38. Ten-year experience with low-dose cyclosporine A in renal transplantation
- Author
-
Wauters, J. P., Rosman, J. B., Eric Descombes, Genton, A., and Mosimann, F.
39. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. No good evidence to promote a general use of sevelamer
- Author
-
Q. V. Nguyen and Eric Descombes
- Subjects
medicine.medical_specialty ,business.industry ,medicine.drug_class ,medicine.medical_treatment ,Sevelamer ,Phosphate binder ,Nephrology ,Internal medicine ,Coronary artery calcification ,Good evidence ,medicine ,Cardiology ,Hemodialysis ,business ,Cardiovascular mortality ,medicine.drug - Abstract
To the Editor: There is little doubt that coronary calcification is associated with cardiovascular mortality.
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.